tbuckley/cabot-search huggingface dataset:
Book Listings
Journal: Annals of Internal Medicine (2002)

Book Listings5 March 2002Book ListingsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-136-5-200203050-00027 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail CardiologyAuscultation Skills: Breath and Heart Sounds2nd edition. Springhouse. 268 pages. Springhouse, PA: Springhouse Corporation; 2002. $50.00. ISBN 1582551588. Order phone 800-588-7738.Cardiac Arrhythmias 2001A Raviele, ed. 657 pages. New York: Springer-Verlag; 2002. $109.00. ISBN 8847001609. Order phone 800-777-4643.Cardiology: Current PerspectivesG Jackson, ed. 404 pages. Philadelphia: Taylor & Francis; 2002. $99.00. ISBN 185317629X. Order phone 800-821-8312.Catheter Ablation of Arrhythmias2nd edition. DP Zipes and M Haissaguerre, eds. 432 pages. Armonk, NY: Futura; 2002. $98.00. ISBN 0879934980. Order phone 800-877-8761.Congenital Heart Disease in the AdultWM Gersony and MS Rosenbaum. 304 pages. New York: McGraw-Hill; 2002. $99.00. ISBN 0070329095. Order ... Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 March 2002Volume 136, Issue 5Page: B1KeywordsComputed axial tomographyHealth careMilkPrevention, policy, and public healthRacial and ethnic issues ePublished: 5 March 2002 Issue Published: 5 March 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.Loading ...
Correction
Journal: BMJ (1958)

ANY QUESTIONS ?BRIrisH the attacks is a temporary vascular spasm, and if, as is pre- sumably the case, the scotoma affects only one eye, the site of the spasm is most likely to be in the retina, or possibly in the optic nerve.If, however, both eyes are affected, then the site of the lesion is iikely to be in the occipital cortex.Recurrent visual disturbances may occur as a "migraine equivalent" without any accompanying headache.In such instances there is usually a family history of migraine.Another, but remote, possibility is some unusual vascular anomaly such as an angioma or small aneurysmal dilatation in the neighbourhood of the optic nierve which intermittently becomes increased in size and mnterferes with the blood supply of the macular fibres of the optic nerve, but by now it would almost certainly have caused some permanent defect of central vision.Weight Changes in Menstrual Cycle Q.-What changes in weight are associated with the stages
Correction
Authors: Not Available Not Available
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CANCER PATIENTS AT RISK OF DRUG INTERACTIONS
Journal: CA A Cancer Journal for Clinicians (2007)

tumors and with large regional lymph node metastases (P Ͻ 0.0001 for both).For oral cancer, no significant racial or ethnic disparities in stage were noted."Even when you have insurance, there's going to be tremendous variety in terms of deductibles, copayments, and access to care, so even having insurance isn't a guarantee of access to timely and adequate care, and the findings for Medicaid point to this," Halpern says.That point is crucial in the ongoing debate about reforming the US health care system, according to an editorial accompanying the studies."An exclusive focus on the uninsured, although it may be fundamental, is not sufficient," writes Richard C. Wender, MD, President of the ACS and Chair of the Department of Family Medicine at Thomas Jefferson University."Adequacy of coverage and availability of appropriate health care services are equally vital."Preventive care like mammography is known from previous research to be a casualty of inadequate insurance.Indeed, a recent study from the National Cancer Institute (Cancer 2007;109: 2405-2409) cited lack of insurance and higher copays as possible contributors to the 4% decline in US mammography rates from 2000 to 2005.Halpern says his study supports that hypothesis.Affordable access to primary care clinicians and preventive services like cancer screening are central to adequate coverage, Wender stresses."Individuals who have a regular source of primary care are both more likely to be up to date with cancer screening and more likely to receive timely follow up and evaluation for abnormal findings," he writes.
Nonalcoholic Steatohepatitis
Authors: James M. Walker
Journal: Annals of Internal Medicine (1997)

Letters1 September 1997Nonalcoholic SteatohepatitisJames M. Walker, MDJames M. Walker, MDPennsylvania State College of Medicine; Hershey, PA 17033Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-127-5-199709010-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I found it odd that Sheth and colleagues' useful review of nonalcoholic steatohepatitis [1] recommended liver ultrasonography, liver-vessel Doppler ultrasonography, and liver biopsy without providing any estimate for the likelihood of discovering treatable disease in patients in whom the clinical examination and results of preliminary testing are unremarkable. Even when evidence is limited, it would be useful to known what the evidence and its strength are, particularly in the case of liver biopsy. The finite morbidity and mortality associated with this test may well be greater than the likely benefit.References1. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997; 126:137-45. Google Scholar Author, Article, and Disclosure InformationAffiliations: Pennsylvania State College of Medicine; Hershey, PA 17033 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByNon-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects 1 September 1997Volume 127, Issue 5Page: 411KeywordsBiopsyLiverLiver diseasesMorbidityMortalityNonalcoholic steatohepatitisUltrasound imaging Issue Published: 1 September 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Xenobiotic Acceleration of Idiopathic Systemic Autoimmunity in Lupus-Prone BXSB Mice
Authors: K. Michael Pollard, Deborah L. Pearson, Per Hultman, Tricia N. Deane, Ulf Lindh, Dwight H. Kono
Journal: Environmental Health Perspectives (2001)

The diverse genetic backgrounds of lupus-prone murine models, which produce both quantitative and qualitative differences in disease expression, may be a valuable resource for studying the influence of environmental exposure on autoimmune disease in sensitive populations. We tested this premise by exposing autoimmune-prone BXSB and the nonautoimmune C57BL/6 mice to the heavy metal mercury. Although both strains express a nonsusceptible H-2 haplotype, exposure to mercury accelerated systemic autoimmunity in both male and female BXSB mice, whereas the C57BL/6 mice were resistant. The subclasses of antichromatin antibodies elicited in BXSB mice by mercury exposure were more consistent with the predominant Th1-type response of idiopathic disease than with the Th2-type response found in mercury-induced autoimmunity (HgIA). The appearance and magnitude of both humoral and cellular features of systemic autoimmunity correlated with the mercury dose. Furthermore, environmentally relevant tissue levels of mercury were associated with exacerbated systemic autoimmunity. These studies demonstrate that xenobiotic exposure can accelerate spontaneous systemic autoimmunity, and they support the possibility that low-level xenobiotic exposure enhances susceptibility to systemic autoimmunity in genetically susceptible individuals.
Future research directions to characterize environmental mutagens in highly polluted area
Authors: R J Srám
Journal: Environmental Health Perspectives (1996)

Population monitoring using methods of molecular epidemiology combined with reliable data on exposure is an extremely powerful approach to determine the effect of mutagens on human populations.Although human blood and urine have traditionally been used for biomonitoring, an increase in the use of placental and buccal smear samples should be expected.As biomarkers of exposure, DNA strand breaks and hemoglobin and albumin adducts seem to be most sensitive.As biomarkers of response, cytogenetic analysis determining chromosome aberrations or micro- nuclei has been widely used.Additional information can be obtained by using the chromosome painting technique and by determining gene mutations at the hprt locus; however, epidemiological studies exhibiting a relationship between these biomarkers and environmental pollution are still lacking.The use of sperm to analyze the effect of environmental mutagens in germ cells (e.g, sperm morphology and sperm aneuploidy) should be encouraged.The determination of suscepti- bility by analyzing genetic polymorphism, which is responsible for individual differences in the biotransformation of mutagens and carcinogens, will gain importance for risk assessment.Future research should include validating molecular methods, studying adaptive response to chemical carcinogens, and studying the modulatory effect of antioxidants, as well as the effect of carcino- gens on immunity.
FOLDING LOUPE
Authors: William W. Goldnamer
Journal: JAMA (1927)

Perhaps the most frequently used instrument of an ophthalmologist is a good binocular loupe. Frequently it has been my misfortune not to have a loupe with me when away from the office, since I could not ordinarily carry one because of its bulk, as all loupes with which I was acquainted were very bulky. So I had alterations made on a Beebe loupe which would not add to its weight (this loupe was fitted with my correction). The loupe will fit in an ordinary number 5 spectacle case. The obvious advantage of this will be instantly apparent to any ophthalmologist or to other physicians who need such an instrument. The makers of this instrument, George H. Pilling and Son Company, Philadelphia, will be able to supply these folding loupes. 577 Fourteenth Street.
Abstract 582: Tumor immunoediting in a lung cancer mouse model harboring EGFR mutations
Authors: Kazuya Nishii, Kadoaki Ohashi, Kiichiro Ninomiya, Go Makimoto, Hiromi Watanabe, Hirohisa Kano, Naofumi Hara, Heiichiro Udono, Katsuyuki Kiura
Journal: Cancer Research (2019)

Abstract Background: Anti-Programed cell death 1 (PD-1) antibodies such as nivolumab or pembrolizumab show promising treatment effects in smoking-related lung cancer. However, anti-PD-1 antibodies have very little effect on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). EGFR mutations are the most frequent oncogenic drivers in non-smoking related NSCLC. Therefore, we aimed to explore the mechanism underlying tumor immunoediting in a lung cancer mouse model harboring EGFR mutations. Methods: We previously established two strains of transgenic lung cancer mouse (C57BL/6) harboring a mouse Egfr exon 19-deletion (mDEL) or a human EGFR L858R (hLR) mutation, driven by a surfactant protein (SP)-C promoter (Ohashi, Cancer Sci. 2008; Ohashi, Cancer Res. 2009). These mice developed EGFR-dependent multifocal lung adenocarcinomas from type II pneumocytes. We modified the two models by transplanting lung tumors subcutaneously into C57BL/6 (Ohashi, AACR. 2018). Evaluation of mice tumor lymphocyte profile was done through flow cytometry or immunohistochemistry (IHC). Effects of T cell depletion or anti-mouse PD-1 antibody (4H2) in vivo were also assessed. Comprehensive analysis of mRNA expression of immuno-checkpoint molecules in the tumors was performed using PanCancer Immune Profiling Panel (NanoString Technologies). Results: CD4+ T cells and/or CD8+ T cells were depleted in the subcutaneously transplanted tumor model followed by treatment with gefitinib (50 mg/kg/day, 5 days/week) for 2 weeks. As a result, after gefitinib discontinuation, rapid regrowth was seen in the tumors from groups with depletion of CD8+ T cells; depletion of CD4+ T cells had little effect on tumor regrowth, and tumor inhibition continued for 2 weeks after cessation of gefitinib. IHC showed relatively increased numbers of CD4+ T cells in the mice tumors whereas a decrease in the number of CD8+ T cells or Foxp3 positive cells was noted. PD-L1 expression was not observed in the tumors. Consistently, 4H2 showed little effect on tumor growth in vivo. The cancer immune panel showed increased expression of immune mediators such as Ccl6, Clec4n, and Lcn2. Conclusions: Our results suggest that CD8+ T cells can recognize mice tumors in vivo. New immuno-checkpoint molecules regulating CD8+ T cells from PanCancer Immune Profiling Panel were evaluated. Further, we plan to evaluate the efficacy of various immuno-checkpoint inhibitors in vivo. Citation Format: Kazuya Nishii, Kadoaki Ohashi, Kiichiro Ninomiya, Go Makimoto, Hiromi Watanabe, Hirohisa Kano, Naofumi Hara, Heiichiro Udono, Katsuyuki Kiura. Tumor immunoediting in a lung cancer mouse model harboring EGFR mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 582.
Erratum
Journal: BMJ (1911)

EDICALJOU&Nlm i6'igi_ TIIE CRIMTINAL AND THE COMMU-NITY.PISIoXN SURGIEOQN.-Thefollowing books may serve ouir co1rre- spoiAcleiit's purpose: Crimie: Its (c'mtnse tidl hYeldmeslie, by Cesare Lombroso, translated( by H. F. Hortonl (
Chemotherapeutic agents against RNA viruses: ranks swelling
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New therapy for advanced Hodgkin's disease
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Miscellany.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic diversity in hemoglobins. Disease and nondisease
Authors: R. B. Scott
Journal: JAMA (1978)

Recent mass screening programs for sickle cell trait have been the first large-scale efforts to detect potentially deleterious genes and to provide genetic counseling to healthy carriers. In these programs, the expected prevalence of sickle hemoglobin and hemoglobin C has been found, and other mutant hemoglobin genes have also been uncovered. Many of these are not associated with disease, but simply reflect normal genetic diversity. A paradox of this finding is illustrated when, in counseling, many persons demonstrate difficulty in understanding that though they have an abnormal hemoglobin gene, they themselves are not ill or abnormal. The problem's solution lies in educating both health professionals and the public so that the normal existence of considerable genetic diversity is recognized. Since every person may carry mutant genes, whether potentially deleterious or innocuous, our definition of normal must be revised. (<i>JAMA</i>239:2681-2684, 1978)
Editorial: More on liver tumours and the pill.
Journal: BMJ (1975)

An association between hepatic neoplasia and the use of oral contraceptives was first noted in 1973 when 7 women with benign adenomata were described. Since then 46 similar cases have been reported. Most of these had been taking oral contracepives for over 2 years, but in a few cases for less than 6 months. The tumors have usually been solitary. About 2 of each 3 have had acute symptoms of intraperitoneal hemorrhage. Abdominal pain and an abdominal mass have also been present. Liver scanning has shown a filling defect when the tumor was large. Liver function tests have been normal. Liver biopsy is contraindicated because of the danger of hemorrhage. Surgical excision of the tumor is recommended. A case of hepatocellular carcinoma and 1 of hepatoblastoma have been reported in these tumors. Surgeons have found these tumors at laparotomy for other diagnoses. Physicians should be alert to make the diagnosis. All further cases should be reported.
The authors reply
Authors: S. HEXEBERG, S. ROTEVATN, E. HEXEBERG, N. WILLUMSEN, R. K BERGE
Journal: Cardiovascular Research (1993)

Journal Article The authors reply Get access SOFIE HEXEBERG, SOFIE HEXEBERG Search for other works by this author on: Oxford Academic PubMed Google Scholar SVEIN ROTEVATN, SVEIN ROTEVATN Search for other works by this author on: Oxford Academic PubMed Google Scholar ERIK HEXEBERG, ERIK HEXEBERG Search for other works by this author on: Oxford Academic PubMed Google Scholar NINA WILLUMSEN, NINA WILLUMSEN Search for other works by this author on: Oxford Academic PubMed Google Scholar ROLF K BERGE ROLF K BERGE Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 27, Issue 3, March 1993, Page 538, https://doi.org/10.1093/cvr/27.3.538a Published: 01 March 1993
Cevoglitazar, a Novel Peroxisome Proliferator-Activated Receptor-α/γ Dual Agonist, Potently Reduces Food Intake and Body Weight in Obese Mice and Cynomolgus Monkeys
Authors: Hong Chen, Beatriz Dardik, Ling Qiu, Xianglin Ren, Shari L. Caplan, Bryan Burkey, Brian R. Boettcher, Jesper Gromada
Journal: Endocrine Reviews (2010)

ABSTRACT Cevoglitazar is a dual agonist for the peroxisome proliferator-activated receptor (PPAR)-α and -γ subtypes. Dual activation of PPARα and -γ is a therapeutic approach in development for the treatment of type 2 diabetes mellitus and diabetic dyslipidemia. In this report, we show that, in addition to improving insulin sensitivity and lipid metabolism like other dual PPAR agonists, cevoglitazar also elicits beneficial effects on energy homeostasis in two animal models of obesity. In leptin-deficient ob/ob mice, administration of cevoglitazar at 0.5, 1, or 2 mg/kg for 18 d led to acute and sustained, dose-dependent reduction of food intake and body weight. Furthermore, plasma levels of glucose and insulin were normalized after 7 d of cevoglitazar treatment at 0.5 mg/kg. Plasma levels of free fatty acids and triglycerides were dose-dependently reduced. In obese and insulin-resistant cynomolgus monkeys, treatment with cevoglitazar at 50 and 500 μg/kg for 4 wk lowered food intake and body weight in a dose-dependent manner. In these animals, cevoglitazar also reduced fasting plasma insulin and, at the highest dose, reduced hemoglobin A1c levels by 0.4%. These preclinical results demonstrate that cevoglitazar holds promise for the treatment of diabetes and obesity-related disorders because of its unique beneficial effect on energy balance in addition to improving glycemic and metabolic control.